172 related articles for article (PubMed ID: 34634322)
1. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer.
Berkel C; Cacan E
Life Sci; 2021 Dec; 286():120029. PubMed ID: 34634322
[TBL] [Abstract][Full Text] [Related]
2. The role of estrogen and estrogen receptors in chemoresistance.
Sui M; Zhang H; Fan W
Curr Med Chem; 2011; 18(30):4674-83. PubMed ID: 21867480
[TBL] [Abstract][Full Text] [Related]
3. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Mittal R; Chaudhry N; Pathania S; Mukherjee TK
Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
[TBL] [Abstract][Full Text] [Related]
5. Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.
Ali R; Aouida M; Alhaj Sulaiman A; Madhusudan S; Ramotar D
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806243
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
7. Roles of ERα and ERβ in estrogen-induced DDP chemoresistance in non-small cell lung cancer.
Yu N; Dou L; Li Y; Deng L; Wei X; Guo Y
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706665
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin resistance: preclinical findings and clinical implications.
Köberle B; Tomicic MT; Usanova S; Kaina B
Biochim Biophys Acta; 2010 Dec; 1806(2):172-82. PubMed ID: 20647037
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
10. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
12. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin in cancer therapy: molecular mechanisms of action.
Dasari S; Tchounwou PB
Eur J Pharmacol; 2014 Oct; 740():364-78. PubMed ID: 25058905
[TBL] [Abstract][Full Text] [Related]
14. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
15. [Clinical function of estrogen receptors in endometrial cancer].
Caringella AM; Di Naro E; Loverro G
Minerva Ginecol; 2011 Dec; 63(6):495-504. PubMed ID: 22036754
[TBL] [Abstract][Full Text] [Related]
16. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q
Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Ho GY; Woodward N; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():37-46. PubMed ID: 27105947
[TBL] [Abstract][Full Text] [Related]
18. Systems biology of cisplatin resistance: past, present and future.
Galluzzi L; Vitale I; Michels J; Brenner C; Szabadkai G; Harel-Bellan A; Castedo M; Kroemer G
Cell Death Dis; 2014 May; 5(5):e1257. PubMed ID: 24874729
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
[TBL] [Abstract][Full Text] [Related]
20. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
